Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MorphoGel
- Development stage
- Unknown
- Lead developer
- Serina Therapeutics
- Modality
- Peptides
- Administration
- Topical
01
Overview
MorphoGel is a biocompatible, hybrid poloxamer-based hydrogel scaffold developed by Escape Therapeutics. It is designed to support two-dimensional (2-D) and three-dimensional (3-D) stem cell culture, maintaining the multipotency of human mesenchymal stem cells (MSCs) and other somatic and stem cells without requiring enzymatic detachment during scale-up. Additionally, MorphoGel serves as a non-immunogenic, bioactive extracellular matrix scaffold for tissue engineering, including the construction of artificial skin (such as Escape's AlloGraf bilayered skin substitute) to treat scars, burns, and partial-thickness wounds.
- Brand names
- EshellMorphoGel
- Other names
- poloxamer-octapeptide hybrid hydrogel
Beyond the preview
Go deeper on MorphoGel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MorphoGel.